06:38:57 EDT Fri 24 May 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:VKTX - VIKING THERAPEUTICS INC - http://www.vikingtherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VKTX - Q0.162.08·62.982.161.571.1665    99.41  8.2805:48:35Apr 2415 min RT 2¢

Recent Trades - All 5 today
Time ETExPriceChangeVolume
05:48:35Q62.060.496
05:45:01Q62.240.6725
05:17:59Q62.240.6710
04:40:55Q62.000.434
04:40:55Q62.000.4335
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-24 16:05U:VKTXNews ReleaseViking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-04-22 06:00U:VKTXNews Release6 Stocks Positioned to Soar as Investors Focus on MASH
2024-04-17 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
2024-03-26 07:03U:VKTXNews ReleaseViking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
2024-03-04 16:45U:VKTXNews ReleaseViking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
2024-02-28 20:50U:VKTXNews ReleaseViking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
2024-02-27 16:19U:VKTXNews ReleaseViking Therapeutics Announces Proposed Public Offering of Common Stock
2024-02-27 07:03U:VKTXNews ReleaseViking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
2024-02-07 16:05U:VKTXNews ReleaseViking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
2024-01-31 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024
2023-11-13 16:02U:VKTXNews ReleaseViking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting ‚ ® 2023
2023-11-02 16:03U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2023-10-25 16:05U:VKTXNews ReleaseViking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-23 07:05U:VKTXNews ReleaseViking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
2023-10-18 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023
2023-10-17 16:05U:VKTXNews ReleaseViking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
2023-10-10 16:05U:VKTXNews ReleaseViking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
2023-09-07 16:05U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2023-09-06 07:03U:VKTXNews ReleaseViking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
2023-07-26 16:05U:VKTXNews ReleaseViking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update